Literature DB >> 21593735

Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility.

M Dobrinas1, J Cornuz, B Oneda, M Kohler Serra, M Puhl, C B Eap.   

Abstract

Cytochrome P4501A2 (CYP1A2) is involved in the metabolism of several drugs and is induced by smoking. We aimed to determine the interindividual change in CYP1A2 activity after smoking cessation and to relate it to CYP1A2 genetic polymorphisms. CYP1A2 activity was determined from the paraxanthine:caffeine ratio in 194 smokers and in 118 of them who had abstained from smoking during a 4-week period. The participants were genotyped for CYP1A2*1F, *1D, and *1C polymorphisms. Smokers had 1.55-fold higher CYP1A2 activity than nonsmokers (P < 0.0001). The individual change in CYP1A2 activity after smoking cessation ranged from 1.0-fold (no change) to a 7.3-fold decrease in activity. In five participants with low initial CYP1A2 activity, an increase was observed after smoking cessation. Before smoking cessation, the following factors were found to influence CYP1A2 activity: CYP1A2*1F (P = 0.005), CYP1A2*1D (P = 0.014), the number of cigarettes/day (P = 0.012), the use of contraceptives (P < 0.001), and -163A/-2467T/-3860G haplotype (P = 0.002). After quitting smoking, only CYP1A2*1F (P = 0.017) and the use of contraceptives (P = 0.05) had an influence. No influence of CYP1A2 polymorphisms on the inducibility of CYP1A2 was observed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593735     DOI: 10.1038/clpt.2011.70

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

1.  Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Authors:  David R Plowchalk; Karen Rowland Yeo
Journal:  Eur J Clin Pharmacol       Date:  2012-01-19       Impact factor: 2.953

2.  Can valproic acid be an inducer of clozapine metabolism?

Authors:  F J Diaz; C B Eap; N Ansermot; S Crettol; E Spina; J de Leon
Journal:  Pharmacopsychiatry       Date:  2014-04-24       Impact factor: 5.788

3.  Why dried blood spots are an ideal tool for CYP1A2 phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 4.  Blood pressure in relation to coffee and caffeine consumption.

Authors:  Idris Guessous; Chin B Eap; Murielle Bochud
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

5.  Letter in Reply to Arno et al. "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism".

Authors:  Victor Ferreira; Josh J Wang; Eric Villeneuve; Sophie Gosselin
Journal:  Obes Surg       Date:  2017-11       Impact factor: 4.129

6.  Clinical pharmacist's role in implementing a smoking cessation intervention in a Swiss regional hospital: an exploratory study.

Authors:  Maria Dobrinas; Anne-Laure Blanc; François Rouiller; Grégoire Christen; Marcos Coronado; Damien Tagan; Christian Schäli
Journal:  Int J Clin Pharm       Date:  2014-03-04

Review 7.  The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.

Authors:  Meysam Zarezadeh; Ahmad Saedisomeolia; Mahoor Shekarabi; Masoud Khorshidi; Mohammad Reza Emami; Daniel J Müller
Journal:  Eur J Nutr       Date:  2020-11-03       Impact factor: 5.614

Review 8.  Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis.

Authors:  Ayala Shirazi; Brendon Stubbs; Lucia Gomez; Susan Moore; Fiona Gaughran; Robert J Flanagan; James H MacCabe; John Lally
Journal:  Int J Mol Sci       Date:  2016-06-02       Impact factor: 5.923

Review 9.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

Review 10.  Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.

Authors:  Chin B Eap
Journal:  Dialogues Clin Neurosci       Date:  2016-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.